Results 11 to 20 of about 18,139 (185)

Health disparities in chronic liver disease

open access: yesHepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian   +3 more
wiley   +1 more source

Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications [PDF]

open access: yesMental Health Clinician
Introduction Naltrexone is an opioid antagonist that is FDA approved to treat alcohol dependence and opioid dependence. It is available as an oral tablet and an extended-release injectable suspension.
Elena R. Beauregard, PharmD, BCPS   +1 more
doaj   +1 more source

Naltrexone/Bupropion [PDF]

open access: yesDrugs in R&D, 2010
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg.
openaire   +2 more sources

Naltrexone Protects Against Lipopolysaccharide/D-Galactosamine–Induced Hepatitis in Mice

open access: yesJournal of Pharmacological Sciences, 2008
Naltrexone, an opioid receptor antagonist, has been claimed to have anti-inflammatory and immunomodulatory effects both in vitro and in vivo.
Chien-Chuan Wang   +5 more
doaj   +1 more source

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2022
Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S   +5 more
doaj  

The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study

open access: yesFrontiers in Psychiatry, 2010
These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given that one of the most well-established mechanisms of action of naltrexone involves blunting of alcohol reward, it is hypothesized that naltrexone should be ...
Lara Ray   +2 more
doaj   +1 more source

Exploring genetic predictors of naltrexone treatment response in opioid use disorder

open access: yesОбозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2019
Purpose: The present study was aimed to evaluate the effect of the opioid receptors genes and dopamine system genes polymorphisms on the treatment outcomes of opioid dependence with implantable and oral naltrexone in randomized double blinded double ...
Е. A. Blokhina .   +6 more
doaj   +1 more source

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence

open access: yesSubstance Abuse: Research and Treatment, 2011
Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj   +1 more source

Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males

open access: yesAddiction Neuroscience, 2023
The non-selective opioid receptor antagonist, naltrexone is one of the most prescribed medications for treating alcohol and opioid addiction. Despite decades of clinical use, the mechanism(s) by which naltrexone reduces addictive behavior remains unclear.
Cory N. Spencer   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy